Physician profile
Thomas K Lam
NPI 1699194175
$8,177.96
in general payments reported to CMS, 2019-2025
20 companies · $1,728 in 2025
The $1,728 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.48 · 2022: $638 · 2023: $3,035 · 2024: $2,700 · 2025: $1,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,329 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,329.26 |
| Education | $133.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,995.20 | 2021-2025 | |
| Janssen Biotech, INC. | $1,574.72 | 2022-2025 | Tremfya |
| Pfizer INC. | $668.69 | 2023-2025 | |
| Amgen INC. | $536.64 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $530.84 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $410.73 | 2022-2025 | Sotyktu |
| Ucb, INC. | $392.69 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $386.53 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $368.19 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Dermavant Sciences, INC. | $296.66 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $292.29 | 2023-2025 | Zoryve |
| Genzyme Corporation | $228.08 | 2022-2025 | |
| Lilly USA, LLC | $203.15 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $99.81 | 2023-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.98 | 2023-2025 | Spevigo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $37.25 | 2025 | Vtama |
| Leo Pharma INC. | $22.43 | 2025 | Anzupgo |
| Genentech USA, INC. | $16.41 | 2024 | Xolair |
| Galderma Laboratories, L.P. | $16.03 | 2025 | Dysport |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.